Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
ACADIA Pharmaceuticals Inc. |
---|---|
Information provided by: | ACADIA Pharmaceuticals Inc. |
ClinicalTrials.gov Identifier: | NCT00550238 |
To assess the long-term safety and tolerability of ACP-103 in subjects with Parkinson's disease psychosis.
Condition | Intervention | Phase |
---|---|---|
Parkinson's Disease Psychosis |
Drug: pimavanserin tartrate (ACP-103) |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Open Label, Uncontrolled, Single Group Assignment, Safety Study |
Official Title: | A Multi-Center, Open-Label Extension Study to Examine the Safety and Tolerability of ACP-103 in the Treatment of Psychosis in Parkinson's Disease |
Estimated Enrollment: | 500 |
Study Start Date: | July 2007 |
Estimated Primary Completion Date: | December 2009 (Final data collection date for primary outcome measure) |
Ages Eligible for Study: | 40 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Kimberly Wilson | ACP-103clintrials@acadia-pharm.com |
Responsible Party: | ACADIA Pharmaceuticals Inc. ( Kimberly Wilson ) |
Study ID Numbers: | ACP-103-015 |
Study First Received: | October 26, 2007 |
Last Updated: | November 17, 2008 |
ClinicalTrials.gov Identifier: | NCT00550238 |
Health Authority: | United States: Food and Drug Administration |
Parkinson's Disease Psychosis |
Schizophrenia Ganglion Cysts Mental Disorders Movement Disorders Parkinson Disease Basal Ganglia Diseases |
Central Nervous System Diseases Psychotic Disorders Parkinsonian Disorders Neurodegenerative Diseases Brain Diseases Schizophrenia and Disorders with Psychotic Features |
Nervous System Diseases |